Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Zyprexa Marketing Documents Sought By Florida Medicaid Fraud Unit

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

State Attorney General’s investigation could extend to other Lilly products, the company says in an SEC filing.

You may also be interested in...



Lilly To Pay Up To $500 Million In Second Zyprexa Settlement

The settlement resolves suits alleging Lilly inadequately warned patients of the risks of diabetes and hyperglycemia associated with the antipsychotic.

Lilly To Pay Up To $500 Million In Second Zyprexa Settlement

The settlement resolves suits alleging Lilly inadequately warned patients of the risks of diabetes and hyperglycemia associated with the antipsychotic.

Lilly Pleads Guilty To Off-Label Evista Promotion

The company will pay a $36 mil. fine for promoting the osteoporosis drug for reduction in breast cancer risk.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By